Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 19/20 | 1.00 |
| ▸ | CDK1 | P06493 | 16/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 16/20 | 1.00 |
| ▸ | CDK9 | P50750 | 16/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 15/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 15/20 | 1.00 |
| ▸ | CDK7 | P50613 | 15/20 | 1.00 |
| ▸ | CCNH | P51946 | 14/20 | 1.00 |
| ▸ | CDK4 | P11802 | 14/20 | 1.00 |
| ▸ | CCND1 | P24385 | 12/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.54 |
| ▸ | CCND3 | P30281 | 1/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1531479 | 0.86 | CDK2 (1.00) | CDK2CDK1CCNE1CDK9CCNT1 | |
| SCHEMBL1531503 | 0.86 | CDK2 (1.00) | CDK2CDK1CCNE1CDK9CCNT1 | |
| SCHEMBL1531473 | 0.84 | CDK2 (1.00) | CDK2CDK1CCNE1CDK9CCNT1 | |
| SCHEMBL1531520 | 0.82 | CDK2 (1.00) | CDK2CDK1CCNE1CDK9CCNT1 | |
| SCHEMBL11295191 | 0.81 | CDK2 (0.74) | CDK2CDK1CCNE1CDK9CCNT1 | |
| SCHEMBL1531440 | 0.81 | CDK2 (1.00) | CDK2CDK1CCNE1CDK9CCNT1 | |
| SCHEMBL1531510 | 0.80 | CDK2 (1.00) | CDK2CDK1CCNE1CDK9CCNT1 | |
| SCHEMBL2279003 | 0.79 | CCNT1 (0.67) | CDK2CDK1CCNE1CDK9CCNT1 | |
| SCHEMBL1531474 | 0.78 | CDK2 (1.00) | CDK2CDK1CCNE1CDK9CCNT1 | |
| SCHEMBL11295188 | 0.78 | CDK2 (0.69) | CDK2CDK1CCNE1CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4653741-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| EP-1641805-B1 | THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROTEIN KINASES | CYCLACEL LTD (GB) | 2010-01-13 | — | — | EP | claimed |
| US-7576091-B2 | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | CYCLACEL LIMITED (GB) | 2009-08-18 | — | — | US | claimed |
| JP-2007516202-A | — | — | 2007-06-21 | — | — | JP | claimed |
| US-20060264628-A1 | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | CYCLACEL LIMITED (GB) | 2006-11-23 | — | — | US | claimed |
| EP-1641805-A1 | THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROTEIN KINASES | Cyclacel Limited (GB) | 2006-04-05 | — | — | EP | claimed |
| WO-2005005438-A1 | THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROT EIN KINASES | CYCLACEL LIMITED (GB) | 2005-01-20 | — | — | WO | claimed |
| EP-1641805-B1 | THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROTEIN KINASES | CYCLACEL LTD (GB) | 2010-01-13 | — | — | EP | disclosed |
| EP-1641805-B1 | THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROTEIN KINASES | CYCLACEL LTD (GB) | 2010-01-13 | — | — | EP | disclosed |
| US-7576091-B2 | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | CYCLACEL LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| US-7576091-B2 | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | CYCLACEL LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| US-7576091-B2 | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | CYCLACEL LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| US-20060264628-A1 | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | CYCLACEL LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1641805-A1 | THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROTEIN KINASES | Cyclacel Limited (GB) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005005438-A1 | THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROT EIN KINASES | CYCLACEL LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264628-A1 | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | CDK10, CSNK1A1L, CDK20 | CDK2 129/4885CDK1 72/4885CCNE1 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.